| __timestamp | Evotec SE | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 17990000 | 612613000000 |
| Thursday, January 1, 2015 | 25166000 | 650773000000 |
| Friday, January 1, 2016 | 27013000 | 619061000000 |
| Sunday, January 1, 2017 | 42383000 | 628106000000 |
| Monday, January 1, 2018 | 57012000 | 717599000000 |
| Tuesday, January 1, 2019 | 66546000 | 964737000000 |
| Wednesday, January 1, 2020 | 77238000 | 875663000000 |
| Friday, January 1, 2021 | 105445000 | 886361000000 |
| Saturday, January 1, 2022 | 156190000 | 997309000000 |
| Sunday, January 1, 2023 | 169610000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Evotec SE, a dynamic biotech firm, offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.
Takeda's SG&A expenses have shown a consistent upward trend, peaking at approximately 1.05 trillion yen in 2023, marking a 72% increase from 2014. This growth reflects Takeda's strategic investments in global expansion and innovation.
Evotec, on the other hand, has experienced a remarkable surge in SG&A spending, with a nearly tenfold increase from 2014 to 2023. This rapid growth underscores Evotec's aggressive scaling and strategic partnerships.
While Takeda's spending dwarfs Evotec's, the latter's growth trajectory is noteworthy. Missing data for 2024 suggests a need for cautious interpretation.
Comparing SG&A Expenses: Johnson & Johnson vs Evotec SE Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and argenx SE
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs BeiGene, Ltd. Trends and Insights
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Veracyte, Inc. Trends and Insights
Takeda Pharmaceutical Company Limited vs Vericel Corporation: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Evotec SE
Wave Life Sciences Ltd. vs Evotec SE: SG&A Expense Trends
Evotec SE and Xencor, Inc.: SG&A Spending Patterns Compared
Evotec SE and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared